Incretin-based therapies: dealing with safety concerns Long-term safety concerns related to the induction of tachycardia (GLP-1 receptor agonists only), a potential risk of pancreatitis, pancreatic cancer, thyroid cancer, colon cancer, cholecystitis and heart failure (in a trial with saxagliptin) have been expressed [4, 16]
Within the first week or two, they're already feeling the difference
Understanding your individual metabolic and genetic profile can support a more personalized conversation with your healthcare provider about whether semaglutide or an alternative GLP-1 therapy aligns with your specific physiology
Research on the early diagnosis of OC is still ongoing, and recent years have seen a summary of OC methylation biomarkers, as shown in Table 4
Thomas Kruse and Sren stergaard reflect on the development of the GLP-1 analogue, semaglutide, which is reshaping peptide therapeutics in type 2 diabetes, weight management, and beyond
However, in the teenage years, there were significant reductions in sun protection indicating an even greater need for intervention in this group
